BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

DBT opens NIBEC for assessing clinical immunogenicity of viral vaccines

07 September 2020 | News

The laboratory has already started associating closely with leading Indian vaccine manufacturing companies



National Immunogenicity & Biologics Evaluation Center (NIBEC) in Pune for assessing clinical Immunogenicity of viral vaccines is established jointly by Bharati Vidyapeeth University through its constituent unit Interactive Research School for Health Affairs (IRSHA) and BIRAC-DBT, Government of India through National Biopharma Mission.

The facility was inaugurated virtually by Dr Renu Swarup, Secretary, DBT, Government of India in an e-inauguration ceremony presided by Dr Vishwajeet Kadam, Minister of State; Government of Maharashtra.

NIBEC, having a dedicated area of about 10,000 sq ft, was established in a record time of just a year. It has state of the art one BSL-3+, 4 BSL-2 and 10 BSL-1 laboratories.

Key immunogenicity evaluation tests like Plaque Reduction Neutralization Test (PRNT), Microneutralization assay, IgM and IgG ELISA have been developed, standardized and validated for Dengue, Chikungunya and SARS-CoV-2 viruses.

The laboratory has already started associating closely with leading Indian vaccine manufacturing companies and National and International institutes engaged in vaccine developments.

Inaugurating the facility via video conference, Dr Renu Swarup, Secretary, DBT, said that she has very high expectations from NIBEC with regards to clinical immunogenicity testing of vaccine candidates specially with the COVID 19 vaccine pipeline in the country. She further elaborated that having domestic capabilities maintaining international standards in this space, will accelerate and fast track development of indigenous vaccines in the country.